BRIEF—PTC and Odylia ink R&D pact

PTC Therapeutics and Odylia Therapeutics have signed a deal to develop novel gene therapies in rare inherited retinal diseases (IRDs), using the Anc80 vector system developed by researchers at Massachusetts Eye and Ear.

The lead program in the collaboration will be RP-GRIP1, a ciliary protein that is defective in Leber Congenital Amaurosis 6 (LCA6), a rare early onset childhood retinal dystrophy.

PTC chief scientific officer Mark Pykett said: "This partnership combines PTC's strength in developing and commercializing treatments for rare diseases with Odylia's novel vector platform and breadth of expertise in rare ophthalmic diseases.”